青海省祁连县羊布鲁氏病发生情况调查及防治

羊布鲁氏杆菌病俗称布病,是由布鲁氏杆菌感染引起的一种人畜共患病。近年,我国家畜饲养量不断增加,动物及其产品流通不断频繁,部分地区布鲁氏杆菌病呈现上升趋势,严重威胁当地畜牧养殖产业和人民群众的身体健康。该文主要就祁连县羊布鲁氏杆菌病的发生情况进行调查,提出相应的防治对策。     

羊传染性胸膜肺炎防治

羊传染性胸膜肺炎是一种高度接触性传染性疾病,致病原是肺炎支原体。妊娠阶段的母羊受到病原侵染后表现为流产产下死胎,并表现出明显的繁殖障碍。近年,此病发生率逐年升高,造成的死亡现象不断增强,严重威胁养殖产业健康发展。作为养殖管理人员,应从该种疾病的流行病学、临床表现、病理变化和诊断方法等多角度入手,构建针对性的防治措施,严格落实预防为主的原则,为提高养殖效益奠定坚实的技术支撑。该文主要探讨羊传染性胸膜肺炎的防治过程。     

羊传染性脓疮皮炎治疗

羊传染性脓痂皮炎又被称为羊传染性脓疱病、羊口疮病,是由羊传染性脓疱病毒感染引发的一种急性接触性传染性疾病。羊养殖主产区均有发生,是一种常见疾病。羊传染性脓痂皮炎虽然造成的死亡率较低,但是会严重影响羊群正常采食,造成营养物质供给不足,身体逐渐消瘦,抵抗能力变差,易继发感染多种传染性疾病,表现出复杂的临床症状,威胁羊群健康。     

猪副嗜血杆菌病诊断与防治

猪副嗜血杆菌病作为对猪群生长发育带来严重危害性的一种细菌性传染疾病,不仅导致猪群质量下降,降低生猪养殖产业的经济效益。猪副嗜血杆菌病不会造成猪群较高的死亡率,但是对猪群在生长发育中的抵抗能力下降,极易感染多种传染性疾病,导致症状复杂,不利于疾病的诊断。该文主要对猪副嗜血杆菌病的诊断展开分析,论述流行特点、病例变化、临床症状等,并总结猪副嗜血杆菌病的防治方法。     

牛肺疫临床症状及综合防治

牛肺疫又被称为牛传染性胸膜肺炎,是由肺炎支原体感染引发的急慢性呼吸道疾病,临床上主要表现为呼吸急促,呼吸困难,从鼻腔中流出脓性分泌物,主要对患病牛的肺脏、胸膜和淋巴结造成危害,典型的临床特征是肺小叶浆液性肺炎和肺实质纤维素性肺炎,被国际兽医局划归为A类动物疫病,我国将其划归为一类重大动物疫病,发生流行后,需要执行严格的扑杀、无害化处理制度,逐渐净化牛群,避免疫情进一步扩展蔓延到造成更为严重的经济损失。该文主要论述牛肺疫的临床症状和综合防治措施。     

灰铸铁生产技术的一些新进展

对灰铸铁的研究现状和生产中的一些新技术做了评述。重点介绍了高强度薄壁灰铸铁的生产现状以及先进的制造工艺和先进的制造手段在灰铸铁生产中应用所取得的技术成果。     

Canine transmissible venereal tumour: a review

Canine transmissible venereal tumour (CTVT) is a contagious venereal tumour of dogs, commonly observed in dogs that are in close contact with one another, or in stray and wild dogs that exhibit unrestrained sexual activity. CTVT represents a unique, naturally transmissible, contagious tumour, where the mutated tumour cell itself is the causative agent and perpetuates as a parasitic allograft in the host. Clinical history, signalment and cytological features are often obvious for establishing a diagnosis though biopsy and histological examination may be needed in atypical cases. Most cases are curable with three intravenous injections of vincristine sulphate at weekly intervals. The role of stray and wild dogs makes the disease difficult to control and necessitates sustained animal birth control in stray dogs along with prompt therapy of the affected dogs. This review captures the manifold developments in different areas embracing this fascinating tumour, including its biology, diagnosis and therapeutic alternatives.     

The palliative efficacy of modified Mohs paste for controlling canine and feline malignant skin wounds

In veterinary medicine, the management of malignant skin wounds is highly challenging. We conducted a study on seven case animals (four dogs and three cats) which presented with malignant skin wounds. All seven animals had signs and symptoms which were controlled following treatment with a modified Mohs paste. Upon obtaining informed consent from their owners, the animals requiring management of malignant wounds were enrolled in this study. The modified Mohs paste was prepared by mixing zinc chloride, zinc oxide starch powder, glycerin, and distilled water. The modified Mohs paste was topically applied to and left to remain on the malignant wounds for one hour, under controlled conditions. Once the paste was removed, the wounds were irrigated with a solution of sterile saline. At the first examination, the wounds of each animal were observed for signs of exudate, malodor, and bleeding. In every case, visible improvement was observed immediately after the modified Mohs paste treatment. Specifically, the size of the malignant wounds, and the number of times the dressing gauze required changing, significantly decreased (p < 0.05 and p < 0.01, respectively). The open malignant skin wounds caused by mammary gland tumors disappeared in two cases. The Mohs paste has been shown to be a viable option for the palliative treatment in canine and feline malignant skin wound management.     

Carvedilol in dogs with dilated cardiomyopathy

BACKGROUND: Dilated cardiomyopathy (DCM) is characterized by reduced systolic function, heightened sympathetic tone, and high morbidity and mortality. Little is known regarding the safety and efficacy of beta-blocker treatment in dogs with DCM. HYPOTHESIS: Carvedilol improves echocardiographic and neurohormonal variables in dogs with DCM over a 4-month treatment period. METHODS: Prospective, placebo-controlled, double-blinded randomized study. Dogs with DCM underwent echocardiography, ECG, thoracic radiographs, and neurohormonal profiling, followed by titration onto carvedilol (0.3 mg/kg q12h) or placebo over a 4-week period and subsequently received 3 months of therapy. Primary study endpoints included left ventricular volume and function. RESULTS: Sixteen dogs received carvedilol and 7 received placebo. At study end, 13 carvedilol dogs and 5 placebo dogs were alive. There was no difference in the mean percentage change in left ventricular volume at end-diastole (LVVd), left ventricular end-systolic volume (LVVs), and ejection fraction (EF) between treatment groups, suggesting that both groups experienced similar amounts of disease progression. Carvedilol treatment did not result in significant changes in neurohormonal activation, radiographic heart size, heart rate, or owner perceived quality-of-life. Baseline B-type natriuretic peptide (BNP) predicted dogs in the carvedilol-treated group that maintained or improved their EF over the study duration. CONCLUSIONS AND CLINICAL IMPORTANCE: Carvedilol administration did not improve echocardiographic or neurohormonal indicators of heart function. The lack of effect may be related to severity of disease, carvedilol dose, or brevity of follow-up time. Statistical power of the present study was adversely affected by a high fatality rate in study dogs and small sample size.